MTOR and neoplasm: Since the primary indication for mTOR inhibitor selection was in vitro CRP rather than molecular variations, ETA thus identified several patients (n = 13) with in vitro and largely in vivo response to mTOR inhibition, but where the tumor harbored no known alterations indicative of mTOR activation.